Followers | 20 |
Posts | 5355 |
Boards Moderated | 0 |
Alias Born | 01/04/2012 |
Monday, December 26, 2016 8:52:59 AM
August 2015 CVR’s start showing up in trading accounts. They had been a book entry recorded June 2013 with no record provided to shareholders until now. (Why spend the money if there was no movement on Libigel?)
Abbvie picked up the $350 Priority Review Voucher from United TherapeuticsIsuued (March 10, 2015). August 19th , 2015 the day after Addyi was approved. (I wonder if Dr Louis W. Sullivan swho hasserved on United Therapeutics BOD since 2002 and was Chairman of the BOD for Bosante Libigel development and Merger with ANIP, a hormone manufacturer with large capacity was influential in the PRV acquisition?)
December 19, 2015 patent prosecution adds claims that restoring t-levels reduces risk of Breast Cancer.
May 31, 2016, last patient of 3656 patients completed FDA’s 5 year follow up requirement.
Libigel no longer advertised as an opportunity on AVARX. Even when listed, it never added the CV or Breast Cancer Risk reduction. Last updated Feb 22, 2016. Therefore never publicly shopped around.
Three new patent application have been submitted maintaining continuity of data. Should be some revealing information in the specifications.
ANIP let’s Libigel trademark expire.
To add color to the value of Libigel and the CV discovery:
By 2023 the dyslipidemia market is expected to grow to $37.9 billion with 85.5 % of the market covered by Anip licencing rights.
Dyslipidemia Maket
By 2020, the global hypertension market will be $32 billion.
Hypertension Market
Global Breast Cancer Market is expected to reach $17.2 billion by 2021
Breast Cancer Market
In each of the above global markets, a sizabkle percentage would inlcude post menopausal women.
Pfizer recently acquired Anacor for $5.2 billion. Anacor had one approved product, Kerydin with projected peak sales of $1 Billion which the split 50/50 with Sandoz and a recent NDA filing for Crisaborole with projected peak sales of $1.7 billion. This total projected peak sales of $2.2 billion. Libigel blows this out of the water just by physicians switching existing off label and compounded testosterone prescriptions.
[url]
seekingalpha.com/article/3815966-anacor-pharmaceuticals-expensive[/url][tag]Anacor deal[/tag]
Recent ANIP News
- ANI Pharmaceuticals to Present at the 2024 Jefferies Global Healthcare Conference • GlobeNewswire Inc. • 05/29/2024 08:30:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/24/2024 12:03:53 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/24/2024 12:02:18 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/23/2024 11:58:03 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/23/2024 11:54:13 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/23/2024 11:45:47 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/23/2024 08:06:03 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/22/2024 10:14:28 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/21/2024 09:21:53 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 05/20/2024 08:57:32 PM
- ANI Pharmaceuticals Announces the Launch of Kionex® Suspension • GlobeNewswire Inc. • 05/20/2024 10:50:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/17/2024 10:05:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/17/2024 10:01:01 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 05/17/2024 08:50:06 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 05/16/2024 09:02:43 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/16/2024 09:02:13 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 05/16/2024 08:49:13 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 05/15/2024 08:59:50 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 05/14/2024 11:47:51 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/14/2024 08:11:27 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/13/2024 09:25:29 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/10/2024 11:09:24 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/10/2024 10:55:18 AM
- ANI Pharmaceuticals Reports Record First Quarter 2024 Financial Results and Reiterates 2024 Guidance • GlobeNewswire Inc. • 05/10/2024 10:50:00 AM
- ANI Pharmaceuticals to Participate at Two Upcoming Healthcare Conferences • GlobeNewswire Inc. • 05/01/2024 08:30:00 PM
ILUS Provides an Update on the Binding Term Sheet Signed with Actelis Networks (NASDAQ: ASNS) • ILUS • May 31, 2024 12:52 PM
Element79 Gold To Provide Summary and Update on Active Exploration Program, Community Relations at RMEC on June 4 • ELEM • May 30, 2024 1:18 PM
Branded Legacy Secures Exclusive Extraction Partnership with One of the World's Largest Kava Distributors and Producers • BLEG • May 30, 2024 8:30 AM
ECGI Holdings, Inc. Announces $2 Million Debt-to-Equity Conversion • ECGI • May 30, 2024 8:30 AM
North Bay Resources Reports Assays up to >25% Mg, 0.1% Ni, 0.1% Cu, 0.01% Co, 0.3 ppm Pt at Tulameen Platinum Project, British Columbia • NBRI • May 29, 2024 9:03 AM
One World Products, Inc. Issues Shareholder Update • OWPC • May 29, 2024 8:20 AM